Literature DB >> 8435093

Interaction of halichondrin B and homohalichondrin B with bovine brain tubulin.

R F Ludueña1, M C Roach, V Prasad, G R Pettit.   

Abstract

Halichondrin B is a polyether macrolide of marine origin which binds to tubulin and inhibits microtubule assembly in vitro and in vivo. As is the case with phomopsin A and dolastatin 10, halichondrin B is a non-competitive inhibitor of vinblastine binding to tubulin. Analogous to maytansine, which by contrast is a competitive inhibitor of vinblastine binding, halichondrin B has no effect on colchicine binding, which is greatly stabilized by phomopsin A and dolastatin 10, but not by maytansine. We have previously developed assays which allow sensitive discrimination among the interactions of various ligands with tubulin, and examined the effects of ligands on the reactivity of tubulin sulfhydryl groups and the exposure of hydrophobic areas on the surface of the tubulin molecule. To classify the nature of the interaction between halichondrin B and tubulin, in this study we examined the effects of halichondrin B and its closely related analogue, homohalichondrin B, by these assays. We found that: (1) halichondrin B and homohalichondrin B both inhibited formation of an intra-chain cross-link between two sulfhydryl groups in beta-tubulin, as do phomopsin A, dolastatin 10, maytansine, and vinblastine; (2) halichondrin B resembles maytansine in that it had no effect on alkylation of tubulin sulfhydryl groups by iodoacetamide, unlike phomopsin A, dolastatin 10 and vinblastine, all of which inhibit alkylation; (3) halichondrin B differs from other anti-mitotic drugs in that it enhanced exposure of hydrophobic areas on tubulin; (4) homohalichondrin B, like maytansine and in contrast to phomopsin A, dolastatin 10 and vinblastine, had no effect on exposure of hydrophobic areas; and (5) homohalichondrin B, contrary to maytansine, inhibited alkylation of tubulin sulfhydryl groups in the presence of GTP and MgCl2. In their interactions with the tubulin molecule, halichondrin B and homohalichondrin B appear to have unique conformational effects which differ from those of other drugs and also from the effects of each other as well.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8435093     DOI: 10.1016/0006-2952(93)90079-c

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  10 in total

Review 1.  Antimicrotubular drugs binding to vinca domain of tubulin.

Authors:  Suvroma Gupta; Bhabatarak Bhattacharyya
Journal:  Mol Cell Biochem       Date:  2003-11       Impact factor: 3.396

Review 2.  Eribulin mesylate: mechanism of action of a unique microtubule-targeting agent.

Authors:  Nicholas F Dybdal-Hargreaves; April L Risinger; Susan L Mooberry
Journal:  Clin Cancer Res       Date:  2015-04-02       Impact factor: 12.531

Review 3.  Eribulin -- a review of preclinical and clinical studies.

Authors:  Umang Swami; Imran Chaudhary; Mohammad H Ghalib; Sanjay Goel
Journal:  Crit Rev Oncol Hematol       Date:  2011-04-14       Impact factor: 6.312

Review 4.  Modern natural products drug discovery and its relevance to biodiversity conservation.

Authors:  David G I Kingston
Journal:  J Nat Prod       Date:  2010-12-07       Impact factor: 4.050

5.  Operationally simple and efficient workup procedure for TBAF-mediated desilylation: application to halichondrin synthesis.

Authors:  Yosuke Kaburagi; Yoshito Kishi
Journal:  Org Lett       Date:  2007-02-15       Impact factor: 6.005

6.  Pharmacodynamics (PD) and pharmacokinetics (PK) of E7389 (eribulin, halichondrin B analog) during a phase I trial in patients with advanced solid tumors: a California Cancer Consortium trial.

Authors:  Robert J Morgan; Timothy W Synold; Jeffrey A Longmate; David I Quinn; David Gandara; Heinz-Josef Lenz; Christopher Ruel; Bixin Xi; Michael D Lewis; A Dimitrios Colevas; James Doroshow; Edward M Newman
Journal:  Cancer Chemother Pharmacol       Date:  2015-09-11       Impact factor: 3.333

Review 7.  Tubulin-interactive natural products as anticancer agents.

Authors:  David G I Kingston
Journal:  J Nat Prod       Date:  2009-03-27       Impact factor: 4.050

8.  A landmark in drug discovery based on complex natural product synthesis.

Authors:  Satoshi Kawano; Ken Ito; Kenzo Yahata; Kazunobu Kira; Takanori Abe; Tsuyoshi Akagi; Makoto Asano; Kentaro Iso; Yuki Sato; Fumiyoshi Matsuura; Isao Ohashi; Yasunobu Matsumoto; Minetaka Isomura; Takeo Sasaki; Takashi Fukuyama; Yusuke Miyashita; Yosuke Kaburagi; Akira Yokoi; Osamu Asano; Takashi Owa; Yoshito Kishi
Journal:  Sci Rep       Date:  2019-06-17       Impact factor: 4.379

Review 9.  Bioactive Compounds from Marine Sponges: Fundamentals and Applications.

Authors:  Disha Varijakzhan; Jiun-Yan Loh; Wai-Sum Yap; Khatijah Yusoff; Rabiha Seboussi; Swee-Hua Erin Lim; Kok-Song Lai; Chou-Min Chong
Journal:  Mar Drugs       Date:  2021-04-27       Impact factor: 5.118

10.  Cell cycle perturbations and apoptosis induced by isohomohalichondrin B (IHB), a natural marine compound.

Authors:  D Bergamaschi; S Ronzoni; S Taverna; M Faretta; P De Feudis; G Faircloth; J Jimeno; E Erba; M D'Incalci
Journal:  Br J Cancer       Date:  1999-01       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.